전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-1 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs
AntibodyLimited DatastaleEli LillyPhase 1

Peri operative Cetuximab. (Peri operative Cetuximab.)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Phase1#monoclonal-antibody#Eli
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

ZRC-3277 (Pertuzumab, Pertuzumab (ZRC-3277))

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePreclinical

neoadjuvant (Pertuzumab, Pertuzumab (neoadjuvant))

HER2-positive Breast Cancer; Neoplasms · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab + metronomic chemotherapy)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf)

Breast Cancer; Breast Neoplasm · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Merus
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, Petosemtamab + Pembrolizumab)

Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous · Lung Cancer - Non Small Cell Squamous

#LungCancer-NonSmallCellSquamous#Antibody#Phase2#monoclonal-antibody#LungCancer-NonSmallCellNon-Squam+1
Trials 1Status Recruiting
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
AntibodyLimited DatastaleAbbViePhase 1

Pivekimab Sunirine (Pivekimab Sunirine)

Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase1#monoclonal-antibody#MixedPhenotypeAcuteLeukemia+1
Trials 1Status Recruiting
AntibodyLimited DatastaleGenelux CorporationPhase 2

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Ovarian Cancer; Peritoneal Carcinomatosis · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#monoclonal-antibody#PeritonealCarcinomatosis+1
Trials 1Status Active
CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3
Trials 1Status Active
ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#monoclonal-antibody#AdenocarcinomaoftheStomach+1
Trials 1Status Active
AntibodyLimited DatastaleEmory UniversityPhase 2

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Emory
Trials 1Status Active
AntibodyLimited DatastaleUniversitätsklinikum KölnPhase 2

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases · Cervical Cancer ≥ FIGO IIB and or Lymph

#CervicalCancerFIGOIIBandorLymph#Antibody#Phase2#monoclonal-antibody#CervicalCancerFIGOIIBandorLymphN+1
Trials 1Status Discontinued
AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2
Trials 1Status Recruiting

96 / 121 pages

← PreviousNext →